Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Positive correlation of airway resistance and serum asymmetric dimethylarginine level in COPD patients with systemic markers of low-grade inflammation

Authors Tajti G, Gesztelyi R, Pak K, Papp C, Keki S, Szilasi ME, Mikaczo A, Fodor A, Szilasi M, Zsuga J

Received 11 November 2016

Accepted for publication 16 January 2017

Published 14 March 2017 Volume 2017:12 Pages 873—884

DOI https://doi.org/10.2147/COPD.S127373

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Gabor Tajti,1,2 Rudolf Gesztelyi,3 Krisztian Pak,3 Csaba Papp,1 Sandor Keki,4 Magdolna Emma Szilasi,2 Angela Mikaczo,2 Andrea Fodor,2 Maria Szilasi,2 Judit Zsuga1

1Department of Health Systems Management and Quality Management for Health Care, Faculty of Public Health, 2Department of Pulmonology, Faculty of Medicine, 3Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, 4Department of Applied Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, Hungary

Abstract: The major feature of COPD is a progressive airflow limitation caused by chronic airway inflammation and consequent airway remodeling. Modified arginase and nitric oxide synthase (NOS) pathways are presumed to contribute to the inflammation and fibrosis. Asymmetric dimethylarginine (ADMA) may shunt L-arginine from the NOS pathway to the arginase one by uncoupling and competitive inhibition of NOS and by enhancing arginase activity. To attest the interplay of these pathways, the relationship between ADMA and airflow limitation, described by airway resistance (Raw), was investigated in a cohort of COPD patients. Every COPD patient willing to give consent to participate (n=74) was included. Case history, laboratory parameters, serum arginine and ADMA, pulmonary function (whole-body plethysmography), and disease-specific quality of life (St George’s Respiratory Questionnaire) were determined. Multiple linear regression was used to identify independent determinants of Raw. The final multiple model was stratified based on symptom control. The log Raw showed significant positive correlation with log ADMA in the whole sample (Pearson’s correlation coefficient: 0.25, P=0.03). This association remained significant after adjusting for confounders in the whole data set (β: 0.42; confidence interval [CI]: 0.06, 0.77; P=0.022) and in the worse-controlled stratum (β: 0.84; CI: 0.25, 1.43; P=0.007). Percent predicted value of forced expiratory flow between 25% and 75% of forced vital capacity showed that significant negative, elevated C-reactive protein exhibited significant positive relationship with Raw in the final model. Positive correlation of Raw with ADMA in COPD patients showing evidence of a systemic low-grade inflammation implies that ADMA contributes to the progression of COPD, probably by shunting L-arginine from the NOS pathway to the arginase one.

Keywords: ADMA, airway resistance, nitric oxide, SGRQ, whole-body plethysmography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Alteration of the irisin–brain-derived neurotrophic factor axis contributes to disturbance of mood in COPD patients

Papp C, Pak K, Erdei T, Juhasz B, Seres I, Szentpéteri A, Kardos L, Szilasi M, Gesztelyi R, Zsuga J

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2023-2033

Published Date: 7 July 2017